[SCHEDULE 13G/A] Organon & Co. SEC Filing
The Vanguard Group filed an amended Schedule 13G reporting beneficial ownership of 35,927,524 shares of Organon & Co. common stock, representing 13.82% of the class as of the stated event date 09/30/2025. Vanguard reports 0 shares with sole voting power, 1,689,621 with shared voting power, 33,922,797 with sole dispositive power, and 2,004,727 with shared dispositive power.
The filing classifies Vanguard as an investment adviser and includes the standard certification that the securities were acquired and are held in the ordinary course of business and not to change or influence control. Vanguard notes its clients have rights to dividends or sale proceeds related to the reported securities, with no single client interest exceeding five percent.
- None.
 
- None.
 
Insights
Routine 13G/A disclosing a 13.82% passive stake in OGN.
The Vanguard Group reports beneficial ownership of 35,927,524 shares of Organon & Co., or 
The certification states the holdings are in the ordinary course and not for influencing control, consistent with a passive Schedule 13G filing by an investment adviser. Clients of Vanguard have rights to dividends or proceeds; no single client exceeds five percent of the class.
This is primarily informational regarding ownership concentration. Actual impact depends on portfolio flows and holder decisions; the filing does not specify transactions or strategic intent beyond passive ownership.